Randox Biosciences are delighted to be returning to the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Vienna, Austria from 22nd-25th April. ECCMID brings together industry experts in clinical microbiology and infectious diseases to increase awareness and entice conversation around the need to improve diagnosis, treatment and prevention of infection-related diseases.
As a global diagnostics company, Randox Biosciences are committed to the development of innovative tests across a multitude of disease areas including microbiology and infectious diseases to improve diagnostics worldwide. At ECCMID this year, our Business Development Executives, Lindsey and Georgia, will be available at booth 162 to discuss the multiple offerings of Randox Biosciences in this area. Our product portfolio has major links with antibiotic resistance, a serious global crisis compromising the effectiveness of therapeutic options for the treatment of infections.
Continual reinvestment into research and development partnered with our 30+ years’ experience in the diagnostics industry has empowered us to create pioneering products, targeting multiple disease areas and health concerns worldwide, including antibiotic resistance.
We have developed our Evidence range of multiplex testing platforms, utilising our award-winning Biochip Array Technology (BAT). This has revolutionised the diagnostics industry by facilitating the simultaneous detection of a wide range of disease markers from a single sample, providing a complete patient profile for rapid, accurate diagnosis. Utilising this technology, our molecular diagnostics team have developed a range of products that offer diagnostic, prognostic and predictive solutions across a variety of disease areas including infectious diseases.
Sexually transmitted infections (STIs) present an increasing challenge to world public health, with more than 1 million infections identified every day. According to the World Health Organisation (WHO), 500 million new cases of curable sexually transmitted infections including syphilis, gonorrhoea, chlamydia and trichomoniasis occur each year.
Many infections are asymptomatic and can remain undiagnosed, increasing the risk of unhindered spread in the sexually active population. If left untreated, STIs can impact fertility, increase the risk of ectopic pregnancies and infant mortality1. It is therefore vital that, to avoid preventable health complications, rapid and accurate STI diagnostic tests are available to improve health, while also reducing the burden on healthcare system.
This has led to Randox Biosciences developing a multiplex PCR based test to provide a rapid, efficient and reliable clinical solution to STI detection. Our STI Multiplex Array detects 10 of the most common bacterial, viral and protozoan infections including primary, secondary and asymptomatic co-infections, providing a complete infection profile.
The fact that our test not only detects if an infection is present but also clearly identifies the type of infection, holds a strong connection with the appropriate use of antibiotics, ensuring they are only prescribed when required and subsequently, reducing the onset of antibiotic resistance. A report released by WHO stated how common STIs such as chlamydia, gonorrhoea and syphilis are becoming more difficult to treat as the standard antibiotics are now ineffective due to both misuse and overuse. This is a major concern considering each year, 131 million people are infected with chlamydia, 78 million with gonorrhoea, and 5.6 million with syphilis.
Ian Askew, Director of Reproductive Health and Research at WHO, commented on the new WHO guidelines stating how they,
“reinforce the need to treat STI’s with the right antibiotic, at the right dose, and the right time to reduce their spread and improve sexual and reproductive health.”1
Respiratory tract infections are caused by many viral and bacterial pathogens and are the second most common cause of morbidity and mortality worldwide. Particularly affecting the young, elderly and the immunocompromised, respiratory infections can result in prolonged hospital stays and represent a significant cost burden to public health systems worldwide.2
Our Respiratory Multiplex array provides comprehensive screening for infections of both the upper and lower respiratory tracts. As well as simultaneously detecting 22 infections from a single patient sample, our test also identifies if the infection is bacterial or viral within 6 hours. Given that only bacterial infections can be treated with antibiotics, our respiratory array therefore enables clinicians to correctly identify the specific cause or causes of illness, providing opportunities to tailor treatment and as a result, reduce antibiotic misuse
John Lamont, Chief Scientist at Randox Laboratories, whose team developed the test, commented;
“Current diagnostic testing for respiratory infections takes at least 36 hours to confirm the nature of an infection, and they cannot name and categorise infections as bacterial or viral in the way that this new respiratory test can. C-reactive protein tests, for example, that are currently in use can only indicate whether a bacterial infection is likely. We need more than just guess work to combat the antibiotic resistance pandemic.”
NEW Arrays from Randox Biosciences
Innovation is key at Randox Biosciences and with continual reinvestment into research and development, our team are dedicated to the development of new products to achieve our aim of advancing diagnostics worldwide. At this year’s, ECCMID, we are delighted to welcome you to booth 162 to learn more about just a few of our new tests currently under development, targeting Urinary Tract Infections, Cystic Fibrosis and Sepsis.
Dr. Martin Crockard, Head of Molecular R&D at Randox Biosciences, commented;
“The molecular diagnostics group at Randox Biosciences are continually developing a range of multiplex infection detection arrays to identify specific infection agents, allowing more appropriate use of antibiotics to improve patient care and reduce the onset of antibiotic resistance. ECCMID is a great platform to introduce you to just a few of our recent developments.”
We’d love to talk to you about our molecular product range and exciting new tests under development! Visit our team at booth 162 at this year’s ECCMID!
To arrange a meeting or request more information, contact email@example.com
1-World Health Organisation
2- Lancet Infectious Diseases Report